FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Karachun Rita A</u>					2. Issuer Name and Ticker or Trading Symbol Coherus BioSciences, Inc. [ CHRS ]							elationship o ck all applica Director	able)	,	s) to Issue			
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/04/2024							Officer ( below)	Officer (give title below)		Other (specify below)			
C/O COHERUS BIOSCIENCES, INC. 333 TWIN DOLPHIN DRIVE, SUITE 600					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ine)  Form filed by One Reporting Person						
(Street) REDWO CITY	DWOOD CA		94065				` ,	Transac				Person			<u> </u>			
(City)	(State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date					nth/Day/Year)		ed Date, y/Yea	, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 and 5		5. Amoun Securities Beneficia Owned Fo	s Ily ollowing	6. Owner Form: Dir (D) or Ind (I) (Instr.	rect li lirect E 4) C	7. Nature of ndirect Beneficial Dwnership		
							Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)			(Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	ly Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	/ (A) (D) Date Exercisable		Expiration Date	Amount or Number of Shares		(Instr. 4)							
Stock Option (Right to Buy)	\$1.78	06/04/2024		A		168,000		(1)	06/04/2034	Common Stock	168,000	\$0	168,00	0	D			

## **Explanation of Responses:**

1. The underlying shares subject to the option vest and become exercisable as to 1/3rd of the total number of shares on the one year anniversary of June 4, 2024 and 1/36th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

/s/ Bryan McMichael, as Attorney-in-Fact for Rita A.

06/05/2024

Karachun

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.